Summary of Consolidated Financial Results for the Six Months Ended September 30, 2024[IFRS]

(Amounts less than one million yen are rounded down to the nearest million yen.)

1. Consolidated financial results for the six months ended September 30, 2024 (from April 1, 2024 to September 30, 2024)

(1) Consolidated results of operations

(Percentage figures represent changes from the same period of the previous fiscal year.)
Six months ended Revenue Business contribution profit Operating profit
Millions of yen % Millions of yen % Millions of yen %
September 30, 2024 583,729 5.6 17,836 679.4 (713) -
September 30, 2023 552,763 4.1 2,288 211.3 785 -
Six months ended Profit before tax Profit for the period Profit attributable to owners of the Company
Millions of yen % Millions of yen % Millions of yen %
September 30, 2024 (10,025) - (10,739) - (10,714) -
September 30, 2023 (3,746) - (4,496) - (4,492) -
Six months ended Basic earnings per share Diluted earnings per share
Yen Yen
September 30, 2024 (21.66) (21.66)
September 30, 2023 (9.09) (9.09)

(Notes)

1.“Business contribution profit” is calculated by deducting the cost of sales and selling, general and administrative expenses from revenue.

2.Total comprehensive income for the six months ended September 30, 2024 and 2023, was (28,379) million yen and 34,177 million yen (a decrease of 42.0% year-on-year), respectively.

3.Basic earnings per share and diluted earnings per share are calculated based on the profit attributable to owners of Konica Minolta, Inc. (the “Company”).

(2) Consolidated financial position

As of Total assets Total equity Equity attributable to owners of the Company Equity ratio attributable to owners of the Company
Millions of yen Millions of yen Millions of yen %
September 30, 2024 1,323,982 522,708 508,010 38.4
March 31, 2024 1,388,052 553,382 539,816 38.9

2. Dividends per share

  End of the three-month period End of the six-month period End of the nine-month period End of the year Total
Yen Yen Yen Yen Yen
Fiscal year ended
March 31, 2024
- 0.00 - 5.00 5.00
Fiscal year ending
March 31, 2025
- 0.00      
Fiscal year ending
March 31, 2025 (forecast)
    - 0.00 0.00

(Note)Changes from the latest dividend forecasts: None

3. Consolidated forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Percentage figures represent changes from the previous fiscal year.)
Fiscal year ending Revenue Business contribution profit Operating profit Profit attributable to owners of the Company Basic earnings per share
Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen
March 31, 2025 1,134,000 2.4 42,000 26.0 (14,000) - 0 -100.0 0.00

(Notes)

1.Changes from the latest consolidated forecasts: Yes

2.Regarding revision of the consolidated forecasts, refer to “Notice Regarding Revision of Full-year Forecasts for Consolidated Financial Results” announced today (November 5, 2024).

3.The Precision Medicine Business will be classified as a discontinued operation from the third quarter ending December 31, 2024. As a result, in the consolidated forecasts for the fiscal year ending March 31, 2025, revenue, business contribution profit, and operating profit represent the amount of continuing operations, and profit attributable to owners of the Company and basic earnings per share represent the sum of continuing operations and the discontinued operation. In addition, the changes from the previous fiscal year have been calculated using the retrospectively revised figures associated with the classification of the discontinued operation.

■ Notes

  1. Significant changes in the scope of consolidation for the six months ended September 30, 2024 : Yes
    Included: - (-)
    Excluded:Two companies Invicro, LLC and Konica Minolta Business Associates Co.,Ltd.
  2. Changes in accounting policies or changes in accounting estimates

    a. Changes in accounting policies required by International Financial Reporting Standards (IFRS): None

    b. Changes in accounting policies other than the above a.: None

    c. Changes in accounting estimates: None

  3. Number of issued and outstanding shares (common stock)

    a. Number of issued and outstanding shares (including treasury shares)
        As of September 30, 2024: 502,664,337 shares
        As of March 31, 2024: 502,664,337 shares

    b. Number of treasury shares
        As of September 30, 2024: 7,845,088 shares
        As of March 31, 2024: 8,180,129 shares

    c. Average number of issued and outstanding shares during the period
        The six months ended September 30, 2024: 494,645,729 shares
        The six months ended September 30, 2023: 494,154,614 shares

(Note)The Company has established the Board Incentive Plan. The shares owned by the trust account relating to this trust are accounted for as treasury shares (1,956,064 shares as of September 30, 2024, and 2,223,585 shares as of March 31, 2024).

■ This summary of quarterly consolidated financial results falls outside the scope of review procedures to be performed by certified public accountants or an audit firm.

■ Explanation concerning the appropriate use of the forecasts for results of operations and other special matters

(Note on the forecasts for the consolidated financial results)

The forecasts for results of operations in this report are based on information currently available to the Company and its subsidiaries (the “Group”) and certain assumptions determined to be reasonable, and are not intended to assure any achievement of the Group’s operations. Actual results may differ significantly from the forecasts due to various factors. For further details of the assumptions that form the basis of the forecasts and other related matters when referring to the forecasts, refer to “1. QUALITATIVE INFORMATION ON FINANCIAL RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2024, (3) Explanation Regarding the Forecasts for the Consolidated Financial Results” in the attached Supplementary Information on page 13.

(Supplementary information for the quarterly financial results and briefing on the quarterly financial results)

The Company will hold a briefing on the quarterly financial results for institutional investors on Tuesday, November 5, 2024. The proceedings and details of the briefing, along with the supplementary information on the quarterly financial results to be presented at the briefing, will be posted on the website of the Group soon after the briefing.